Companies · Pharmaceuticals

NextEvo, Inc.

CONSHOHOCKEN · Pharmaceuticals

Diligence memoA one-page analyst read on NextEvo, Inc. — recommendation, valuation, rhythm, risks.
$600K
Total raised · real
1
Rounds
0.5×
Latest step-up
Top 87%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Jan 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

NextEvo, Inc. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.36× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
  • Within the normal band (136% of peer median) for its niche.
Quiet
  • Last raise 18 mo ago; this sector typically re-raises about every 13 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

NextEvo, Inc. is one of 1610 Pharmaceuticals companies tracked from CONSHOHOCKEN. By capital raised it ranks in the long tail (ahead of 14% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2025-01-13
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500K$1.0M$1.5M$2.0MPre-Seed · 2025-01-13 Raised $100K (real) Modeled valuation $330K (est)$100K$330KPre-Seed2025Pre-Seed · 2025-01-13 Raised $500K (real) Modeled valuation $1.7M (est)$500K$1.7MPre-Seed2025Pre-Seed · 2025-01-13 Raised $600K (real) Modeled valuation $2.0M (est)$600K$2.0MPre-Seed2025Pre-Seed · 2025-01-13 Raised $300K (real) Modeled valuation $990K (est)$300K$990KPre-Seed2025+$500K+$600K+$300KCumulative $1.5M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2025
Pre-Seed extension$500K · 2025
Pre-Seed extension$600K · 2025
Pre-Seed extension$300K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$2.0M
Base estimate est.
$336K
Conservative case
$5.7M
Upside case
$3.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $330K · 2025-01-132025Pre-Seed · modeled $1.7M · 2025-01-13Pre-Seed · modeled $2.0M · 2025-01-13Pre-Seed · modeled $990K · 2025-01-132025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
1.5 yr
Elapsed time used
1.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
1.5 yr
On record since
2025
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$600K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.7× of median
This company$300K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.0M
Sector median$76.1M

Raised more than 14% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 19.

This companyCohort peer
$100K$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Fedora Pharmaceuticals Inc. · Pre-Seed Raised $1.1M · modeled $2.5M (est)PRG FlowChem, Inc. · Pre-Seed Raised $825K · modeled $2.5M (est)Adora Animal Health Corp · Pre-Seed Raised $1.0M · modeled $2.5M (est)ABLi Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $2.2M (est)Etheros Pharmaceuticals Corp. · Pre-Seed Raised $1.7M · modeled $1.9M (est)Neuro-Innovators LLC · Pre-Seed Raised $640K · modeled $1.8M (est)PridCor Therapeutics, LLC · Pre-Seed Raised $1.0M · modeled $1.8M (est)NOXX Therapeutics, Inc. · Pre-Seed Raised $1.5M · modeled $1.7M (est)Vogenx, Inc. · Pre-Seed Raised $750K · modeled $1.5M (est)Accretion Therapeutics, Inc. · Pre-Seed Raised $750K · modeled $1.3M (est)Macrotope, Inc. · Pre-Seed Raised $900K · modeled $1.1M (est)NextEvo, Inc. (this company) Raised $600K · modeled $2.0M (est)NextEvo, Inc.
CompanyStageRaised · realValue · estvs peer med.
Fedora Pharmaceuticals Inc.Pre-Seed$1.1M$2.5M1.72×
PRG FlowChem, Inc.Pre-Seed$825K$2.5M1.70×
Adora Animal Health CorpPre-Seed$1.0M$2.5M1.69×
ABLi Therapeutics, Inc.Pre-Seed$1.0M$2.2M1.53×
NextEvo, Inc. this companyPre-Seed$600K$2.0M1.36×
Etheros Pharmaceuticals Corp.Pre-Seed$1.7M$1.9M1.32×
Neuro-Innovators LLCPre-Seed$640K$1.8M1.23×
PridCor Therapeutics, LLCPre-Seed$1.0M$1.8M1.22×
NOXX Therapeutics, Inc.Pre-Seed$1.5M$1.7M1.18×
Vogenx, Inc.Pre-Seed$750K$1.5M1.00×
Accretion Therapeutics, Inc.Pre-Seed$750K$1.3M0.91×
Macrotope, Inc.Pre-Seed$900K$1.1M0.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2025-01-13$556K$330K90%
Pre-Seed$500K2025-01-13$2.8M$1.7M90%
Pre-Seed$600K2025-01-13$3.3M$2.0M90%
Pre-Seed$300K2025-01-13$1.7M$990K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2025-01-13
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$500K2025-01-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.0× larger than the prior — scaling up.
    • 1 investor on this round.
  3. Pre-Seed$600K2025-01-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  4. Pre-Seed$300K2025-01-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
Modeled next raise
$300K
Modeled next size est.range $300K$480K
0.5×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Cornelius H. Merlini2025-01
Edward H. Goodwin, III2025-01
Gerald H. Stahlecker2025-01
Gerry McNally2025-01
John McDonagh2025-01
William H. McComb2025-01
Registry & provenance

NextEvo, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2053885
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Goodsprout Co LLCPharmaceuticalsPre-Seed$600K$12.1Msame sector · same stage
Renavance Pharma, Inc.PharmaceuticalsPre-Seed$600K$4.7Msame sector · same stage
Telesis Therapeutics, LLCPharmaceuticalsPre-Seed$615K$13.4Msame sector · same stage
Lavior IncPharmaceuticalsPre-Seed$580K$13.3Msame sector · same stage
TF Tech Ventures, Inc.PharmaceuticalsPre-Seed$625K$8.3Msame sector · same stage
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$576K$7.9Msame sector · same stage
Neuro-Innovators LLCPharmaceuticalsPre-Seed$640K$1.8Msame sector · same stage
Pradama IncPharmaceuticalsPre-Seed$550K$14.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aptevo Therapeutics Inc.PharmaceuticalsSeed$6.7M82%
Nextgen Pharma LlcPharmaSeries A$229.4M82%
NextRNA Therapeutics, Inc.BiotechnologySeries B$480.3M82%
NeXtGen Biologics, INCBiotechnologySeed$346K81%
Lento Bio, IncPharmaceuticalsSeries A$41.9M80%
NextPoint Therapeutics, Inc.BiotechnologySeries C$443.6M80%
PhaseBio Pharmaceuticals IncPharmaceuticalsSeries C$912.3M80%
NextGen MedStaff, LLCOtherPre-Seed$3.2M80%
Frequently asked
How much funding has NextEvo, Inc. raised?
NextEvo, Inc. has raised approximately $600K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is NextEvo, Inc.'s estimated valuation?
Provath's modeled valuation for NextEvo, Inc. is approximately $2.0M (modeled range $336K–$5.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is NextEvo, Inc. at?
NextEvo, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Jan 13.
What does NextEvo, Inc. do and where is it based?
NextEvo, Inc. operates in the Pharmaceuticals sector, based in CONSHOHOCKEN.
Explore related

See where NextEvo, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at NextEvo, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.